glp-1 capsules supplements are everywhere—but do they actually work? As demand for weight-loss drugs grows, companies are cashing in on products that claim to support GLP-1 goals, often with little oversight. Tap the Amazon.com: Lemme GLP-1 Daily Support,

Gut health: BPC-157 was originally studied for gastrointestinal healing Protects against gut lesions and accelerates intestinal healing Reduces inflammatory cytokines in the gut lining May help with "leaky gut" symptoms that can worsen during menopause Hormonal support (indirect): BPC-157 may support hormone balance by reducing inflammation Gut health plays a crucial role in hormone production and absorption By supporting gut integrity, BPC-157 may indirectly support hormonal health Mood and cognition: Some research suggests BPC-157 interacts with serotonin and dopamine systems May have neuroprotective and antidepressant-like effects Could support the cognitive and mood changes that accompany menopause Dosing considerations Typical protocol: Dose: 250-500 mcg daily Administration: Subcutaneous injection or oral (oral has lower bioavailability but may be better for gut-specific issues) Timing: Can be taken any time

Acetyl-L-carnitine (ALCAR) is a naturally-occurring modified amino acid found in many animal-based foods and available as a dietary supplement

Rights and permissions Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made

One of these classes (class I ferroptosis-inducing compounds, erastin derivatives) inhibits GPX4 through the depletion of glutathione, and the other (class II ferroptosis-inducing compounds, RSL3 derivatives) inhibits GPX4 directly, without glutathione depletion

Obesity: a much higher study focus than other metabolic disease areas Precisely classifying the clinical trial types in the metabolic domain can be a fraught affair given the variability of descriptions, but taking a conservative approach to classification clearly reveals that trials involving obesity and overweight outnumber those focused more on type 2 diabetes about four to one

Yamauchi A, et al